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Background: Histologic grade is the most important predictor of the clinical outcome of non-muscle invasive
(Ta, T1) papillary urothelial carcinoma (NMIPUCa), but its ambiguous criteria diminish its power to predict
recurrence/progression for individual patients. We attempted to find an objective and reproducible histologic
predictor of NMIPUCa that correlates well with the clinical outcome.
Methods: A total of 296 PUCas were collected from the Departments of Surgical Pathology of 11 institutions in
South Korea. The clinical outcome was grouped into no event (NE), recurrence (R), and progression (P) categories.
All 25 histological parameters were numerically redefined. The clinical pathology of each case was reviewed
individually by 11 pathologists from 11 institutions based on the 2004 WHO criteria and afterwards blindly
evaluated by two participants, based on our proposed parameters. Univariate and multivariate logistic regression
analyses were performed using the R software package.
Results: The level of mitoses was the most reliable parameter for predicting the clinical outcome. We propose a
four-tiered grading system based on mitotic count (> 10/10 high-power fields), nuclear pleomorphism (smallest-to-
largest ratio of tumor nuclei >20), presence of divergent histology, and capillary proliferation (> 20 capillary lumina
per papillary core).
Conclusions: The level of mitoses at the initial bladder biopsy and transurethral resection (TUR) specimen appeared
to be an independent predictor of the Ta PUCa outcome. Other parameters include the number of mitoses, nuclear
pleomorphism, divergent histology, and capillary proliferation within the fibrovascular core. These findings may
improve selection of patients for a therapeutic strategy as compared to previous grading systems.
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Table 1 Clinical characteristics of the patients
Stage
Ta (n = 178) T1 (n = 118)
Clinical subgroup (NE/R/P) 73/69/37 32/50/30
Age (mean) 65 68
Sex (M/F) 138/40 93/25
Number of tumor (single vs. multiple) 99/79 46/70a
Size (≤3 cm vs. > 3 cm) 130/48 68/50
NE No event, R Recurrence, P Progression
anot available in 2 cases
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Non-muscle invasive papillary urothelial carcinomas
(NMIPUC) of the urinary bladder, with tumors staged as
non-invasive intraepithelial (Ta) or tumors with invasion
of the lamina propria/submucosa (T1), are known to
recur frequently (in up to 70% of cases), and occasionally
(in up to 40% of cases) progress [1]. The European Asso-
ciation of Urology (EAU) guidelines for NMIPUC-(pTa/
T1) of the bladder proposed risk stratification for
progression into low-, intermediate-, and high-risk
groups [2]. The same guideline stated that the patients
in different groups should be managed using different
strategies. Besides stage (Ta vs. T1), size (< 3 cm vs. >
3 cm), number of papillary tumors (single vs. multiple),
concurrent carcinoma in situ (CIS), and a history of re-
currence, the best estimator of risk is the histological
grade. The four existing grading systems (1973 World
Health Organization [WHO], 1998 International Society
of Urologic Pathology [ISUP]/2004 WHO, Cheng et al.
[3, 4], and 2016 WHO classifications) have divided PUCs
based on subjective morphological parameters, which
has led to a high interobserver/intraobserver variability
in diagnoses made by pathologists, as well as lower pre-
dictive power in management by urologists [5]. In view
of this, alternative grading systems have been sought to
improve the grading discrepancy [6]. Many studies on
immunohistochemical and molecular markers have been
conducted to reduce the subjectivity of the histological
grading systems, but the markers studied have been
declared as having no potential for playing a role in
grading schemes [7–12].
The present study was conducted to identify more ob-
jective and reproducible histological predictors that may
correlate well with the clinical outcome, and compare
these to the previous histological grading systems.
Eleven uropathologists evaluated light microscopic
histological parameters together in three rounds, using a
multihead microscope. Through this study, vigorous
attempts were made to select all possible histological
parameters as countable variables. Each parameter was
evaluated using univariate and multivariate analyses, to
determine whether these variables had statistically sig-
nificant effect in predicting the clinical outcome.
Methods
Patient selection
Surgically removed NMIPUCs of the urinary bladder
were collected from the surgical pathology archives of
11 institutions in South Korea. The inclusion criteria
were as follows: (1) pTa or pT1 stage at the initial blad-
der biopsy; and (2) a 5-year minimum follow-up period
for non-event (NE) cases. The exclusion criteria, on the
other hand, were as follows: (1) a prior history or the
concurrent presence of urothelial carcinoma either inthe ureter or in the renal pelvis; and (2) evidence of as-
sociated urothelial carcinoma in situ. A total of 296
cases were retrieved (Ta, 178; T1, 118). The number of
cases contributed by each institute was 95, 47, 38, 22,
21, 21, 17, 15, 14, 4, and 2.
Clinical parameters
The retrieved cases were classified into three clinical
subgroups: no event (NE), recurrence (R), and progres-
sion (P). NE was defined as cases with no evidence of
tumor on the follow-up imaging study, urine cytology,
or cystoscopy for at least 5-year follow-up duration; R
was defined as cases showing a new tumor occurrence
with the same or lower stage at least 3 months after the
initial resection; and P was defined as a cases showing
new tumor development with a higher stage than the
initial stage, or metastasis to the lymph nodes or other
organs. We collected clinical information on the patients
from the medical records, including 1) age, 2) sex, 3)
site, number, and size/volume of tumor in first biopsy, 4)
interval to the 2nd event, 5) number of recurrences, 6)
the type of final operation, 7) survival, 8) cause of death,
and 9) site of metastasis. All types of specimens (cysto-
scopic biopsy, cold-cup biopsy, transurethral resection of
bladder tumor) were included, but were not defined
separately. However, there was no partial or radical cyst-
ectomy specimen (as an initial biopsy) among the 296
cases. The number of tumors was divided into two
groups: single vs. multiple. The tumor size was also di-
vided into two groups: < 3 cm vs. > 3 cm. The distribu-
tion of each group is shown in Table 1.
Histological evaluation
For microscopic examination, hematoxylin and eosin
(H&E)-stained glass slides of formalin-fixed, paraffin-
embedded tissue of the tumors were retrieved. Interob-
server discrepancy had been solved through several
round-table multihead microscopic examinations involv-
ing 11 pathologists from 11 institutions, during which
consensus opinion was reached. Although the proper
muscle inclusion was not verified by the reviewers in all
samples, 11 contributors had reviewed the original
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view, but also from the surgical records. The 2nd biopsy
was routinely performed 3 months later for check-up of
incomplete resection (i.e., residual tumor). Even if the
initial diagnosis was NMIPUCa (Ta, T1), the cases with
a short-interval change in the T stage were excluded and
were regarded as an inaccurate diagnosis. The clinical
pathology of each case was reviewed individually by 11
pathologists from 11 institutions based on the 2004
WHO criteria and was afterward blindly evaluated by
two participants, based on our proposed parameters.
The histological parameters that were examined are
shown in Table 2 and Figs. 1 and 2. For prediction com-
parison, the previous grading systems, i.e., the 2004
WHO grading, Papillary urothelial neoplasm low malig-
nant potential (PUNLMP) /Low grade (LG) /High grade
(HG), 1973 WHO, Transitional cell carcinoma (TCC)
grade 1/2/3, and Cheng et al., grade 1/2/3/4, were uti-
lized [3, 4].
Statistical analysis
All of the aforementioned parameters were evaluated in
two paired comparison groups (i.e., R vs. NE and P vs.
NE) at each stage. To identify the factors influencing R
and/or P, univariate and multivariate logistic regression
analyses were performed. To investigate the diagnostic
utility of the new grading system, it was compared with
the previous grading systems by area under the curve
(AUC) of receiver operating characteristics (ROC)
curves. All the statistical analyses were performed in the
R software package (R version 3.1.2, R Foundation for
Statistical Computing, Vienna, Austria; <http://www.R-
project.org/>).
Results
Univariate analysis
For PUC-Ta, among morphologic variables, the number
(odds ratio [OR] 0.34 [95% confidence interval, CI: 0.17-
0.67]; p-value = 0.002), size (OR 2.27 [95% CI: 1.05-
5.07]; p-value = 0.0399), mitotic count (OR 1.03 [95%
CI: 1.00-1.07]; p-value = 0.0468), mitotic level (OR 1.09
[95% CI: 0.24-4.83]; p-value = 0.010), and capillary
proliferation in fibrovascular cores (OR 1.05 [95% CI:
1.01-1.10]; p-value = 0.0136) were associated with tumor
recurrence. Nuclear pleomorphism showed borderline
significance for association with recurrence of PUC-Ta
(Table 3). The factors associated with PUC-Ta progres-
sion included patient age, cell density, nuclear pleo-
morphism, hyperchromasia, nuclear groove, prominent
nucleoli, necrosis, mitotic count, mitotic level. Capil-
lary proliferation and apoptosis had borderline statis-
tical significance (Table 4). For PUC-T1, the whorling
pattern was associated with recurrence and the mi-
totic level showed borderline significant associationwith recurrence. Divergent histology was associated
with progression only (Additional file 1: Tables S1
and S2).
Proposal of new grading system using more objective
and fewer histological variables for predicting clinical
outcome
Based on the univariate analysis results, three grades
were designed for prediction of the biological behavior
of PUC-Ta. The univariate analysis results for PUC-T1
revealed that only tumor stage influenced the biological
behavior. Thus, once the tumor had invaded the lamina
propria/submucosa, the histological parameters had an
insignificant impact on the clinical outcome. Therefore,
our new grading system was designed focusing on the
prediction of PUC-Ta tumors. To design a new grading
system with more objective and reproducible, yet sim-
pler parameters, we chose mitotic level, mitotic count,
capillary proliferation, and nuclear pleomorphism as
important histological parameters, based on the univari-
ate analysis. All four of these parameters not only had a
statistically significant influence on both recurrence and
progression of PUC-Ta, but were also quantifiable. Add-
itionally, divergent histology was also selected as one of
the parameters in our grading system; even though it
showed an insignificant p-value in both recurrence and
progression of PUC-Ta, it was statistically significant in
terms of progression in PUC-T1 tumors.
Because the mitotic level appeared to be the most
important morphological parameter based on the uni-
variate analysis, the mitotic level was set as the first step
in our proposed new grading system. Grades 1, 2, and 3
were assigned based on mitotic level, i.e., level 1, level 2,
and level 3, respectively. In cases with any additional
unfavorable histological features, including increased
mitotic count (> 10/10 high-power fields), significant
nuclear pleomorphism (smallest-to largest-ratio of tumor
nuclei of >20), presence of divergent histology, and sig-
nificant capillary proliferation (> 20 capillary lumina per
papillary core), the tumors were upgraded: for example,
grade 1 became grade 2, grade 2 became grade 3, and
grade 3 became grade 4. We designed three similar but
slightly different grading schemes.
Comparison of our proposed grading system with
previous grading systems
To investigate the diagnostic and prognostic utility of
our proposed grading system, we compared the previous
grading systems by comparison of AUC values in each
system. All the statistical analyses were performed with
adjustments for age, gender, tumor size, and number of
tumors, to exclude the impact of factors other than
histological parameters. For the prediction of recurrence
of PUC-Ta, the AUCs of three previous grading systems
Table 2 Histologic parameters evaluated in this study
Variables Definition Category Explanation of category
Papillary fusion Fusion of papillae with forming confluent and
complex papillary cores
1 <1/3 area
2 1/3 ~ 2/3 area
3 >2/3 area
Umbrella cells Area with preserved umbrella cells 1 >50% area
2 5-50% area
3 <5% area
Discohesiveness Detached cells from papillae 1 <1/3 area
Refer to Additional file 1: Figure S1. 2 1/3 ~ 2/3 area
3 >2/3 area
Cell density 1 <1/3 areas show more than 2 times normal density
2 1/3 ~ ≤2/3 area shows more than 2 times of normal
density
3 >2/3 area show more than 2 times normal density
or >5% area shows more than 3 times normal density
Nuclear pleomorphism Size of smallest nuclei vs. largest nuclei(regardless
of tangential sectioning)
1 <3
2 3 ≤ and <8
3 8 ≤ and <20
4 ≥20
Multinucleated giant cells Presence of bi-or multinucleated nuclei 0 Absence
1 Presence
Loss of polarity Proportion of cells deviating from the vertical
alignment shown in normal urothelium
1 <5%
2 5-50%
3 >50%
Hyperchromasia Semiquantitative degree of nuclear hyperchromasia 1 diffusely mild
2 diffusely moderate or focally strong
3 diffusely strong
Nuclear groove Proportion of tumor cells without identifiable
nuclear grooves
1 <5%
2 5-50%
3 > 50%
Prominent nucleoli Proportion of cells having prominent nuclei
(recognizable under 10× medium power)
1 <5%
2 5-50%
3 >50%
Whorling pattern Refer to Additional file 1: Figure S1. 0 absent
1 present
Necrosis Degree of necrosis 1 singly spotted
2 focally grouped or multifocally spotted
3 surface necrosis of nests
4 confluent necrosis
Divergent histology Presence and number of glandular, squamous
or micropapillary differentiation
0 absence
1 1
2 2
3 3
Mitotic count Number of mitosis/ 10 consecutive HPFs in
most mitotically active area
CON
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Table 2 Histologic parameters evaluated in this study (Continued)
Mitotic count-CAT Group of mitotic count 1 0-2
2 3-7
3 8-15
4 ≥16
Mitotic level Most highest level of mitotic figures, from base to the
top of the papilla(low 1/3, mid1/3, and high 1/3)
1 <1/3 or no mitosis
2 1/3-2/3
3 >2/3
Apoptosis Number of apoptotic bodies in most active area/one
HPF
1 <10
2 10-100
3 >100
Capillary proliferation Number of capillary in one papillary core CON
CAT Categorical variable, CON Continuous variable, HPF(s) High power field(s)
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grading systems were over 0.7, and it was statistically
significant (p-value <0.05). However, the differences be-
tween them were not statistically significant (Table 5).
As for the prediction of progression of PUC-Ta, the
AUCs of all of the previous and new grading systems
were all larger than 0.7 (p-value <0.05) (Additional file 1:
Figure S1).
Discussion
In this study, we attempted to find an objective and
reproducible histologic predictor of NMIPUCa that
correlates well with the clinical outcome and to com-
pare these to the previous histological grading
systems. We found that the level of mitoses at the
initial bladder biopsy was an independent predictor of
the Ta PUCa outcome; the number of mitoses, nu-
clear pleomorphism, divergent histology, and capillary
proliferation within the fibrovascular core were also
significant factors.
The EAU guideline proposed a three-risk group strati-
fication. In addition to the tumor stage, tumor size,
number of tumors, and association with CIS, histological
grade was an important parameter for predicting
progression [2, 5]. The 2004 and 2016 WHO grading
systems had been modified from 1973 WHO classifica-
tion; recently, in 2012, Cheng et al. developed a modified
system. These systems are similar, but show slight
variation. Each parameter was measured without well-
defined criteria and has led to suboptimal reproducibility
[13–15]. Each parameter was rated in terms of severity
(mild/moderate/severe) or frequency (rare/occasionally/
frequently). In routine pathology practice, pathologists
often encounter a PUC of the bladder showing high mi-
totic activity, but only mild nuclear atypia and minimal
loss of polarity, or in contrast, a case showing moderate
nuclear pleomorphism and mild to moderate loss ofpolarity, but without discernible mitotic activity. In those
cases, grading was not straightforward, because there
was no priority finding depending on the weighted value
among the many criteria, which complicated the grading
assignment, and resulted in low reproducibility.
We attempted to develop a simple and reproducible
grading system that could predict the clinical outcome
in NMIPUC of the bladder. In this study, we included
only cases with available initial-biopsy specimens and
cases with no concurrent CIS. Initially all 11 uropatholo-
gists evaluated all histologic parameters using individual
light microscopes, for three rounds. Twenty-five histo-
logical features with their numerical parameters (e.g.,
categorized grade or absolute number), including mitotic
level and number of mitoses, level of apoptosis, necrosis,
whirling appearance, and capillary proliferation, which
had not been evaluated prior to this study, were selected,
as well as other histological factors mentioned in the
literature. Thereafter, two pathologists blindly evaluated
all 296 cases to determine interobserver reproducibility.
Some parameters appeared to be influenced by fixation
and stain conditions. Therefore, intranuclear groove and
nucleolar prominence, which may be produced by
procedural artifacts, were considered as low-priority
parameters.
In the univariate analysis of T1-stage tumors, only a
divergent histology correlated with progression. We
considered that the pathological stage-factor, with the
presence of stromal (lamina propria/submucosal) inva-
sion, was the most important factor dictating biological
behavior from among the histological factors. This find-
ing was in accordance with the WHO recommendation
that grading is performed only for noninvasive PUC
(PUC-Ta), and with other reports in the literature [16].
Therefore, in this study, the construction of the histo-
logical predictive model was limited to noninvasive (Ta)
tumors, with exclusion of T1 tumors.
Fig. 1 (1) Representative images of histological parameters evaluated in this study. a Schematic figure of papillary fusion. b Delicate papillae with no
fusion. c Papillary fusion (the arrow marks an imaginary fusion line). d Confluent fusion of papillae. e Presence of umbrella cells (arrowhead). f Absence
of umbrella cells. g Schematic figure for the estimation of cell density based on the distance between cells. h Cell density score 1. i Cell density score
2. j Cell density score 3. k Discohesiveness (l). Nuclear pleomorphism category 4 based on a difference between the smallest and the biggest nucleus
of the tumor cells of about 20-fold.m Multinucleated giant cells. n Mild nuclear hyperchromasia. o Moderate nuclear hyperchromasia. p Severe nuclear
hyperchromasia. q Polarity loss score 2
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histologic parameters that influenced the clinical outcome.
Among the clinical factors, the number and size of tumors
correlated with recurrence, while patient’s age was associ-
ated with progression. In terms of histological factors,
mitotic count, mitotic level, and capillary proliferation
correlated with recurrence. Cell density, nuclear pleo-
morphism, hyperchromasia, nuclear groove, prominent
nucleoli, necrosis as well as mitotic count and level corre-
lated with progression. Apoptosis and capillary prolifera-
tion disclosed borderline significance for progression.It is worth noting that mitotic count showed the high-
est OR in the prediction of both recurrence and progres-
sion of PUC-Ta. In the early twenty-first century, many
studies had focused on mitotic index (Ki-67, AgNO3) of
Ta/T1 urothelial carcinomas, and have reported those as
associated with tumor recurrence [17–19]. However, the
impact of mitosis has not been fully evaluated for use, or
has not been applied with a detailed cutoff-value in the
grading system, in contrast to other epithelial cancers in
other organs (low vs. high serous carcinoma of the ovary,
histological grade of breast cancer and etc.) [20, 21]. Our
Fig. 2 (2) Further representative images of histological parameters evaluated in this study. a Example of a nuclear groove (arrow). b Prominent
nucleoli. c Whorling pattern. d Single spotty necrosis (arrow). e Multifocal group necrosis (arrows). f Surface necrosis. g Confluent necrosis.
h Glandular differentiation. i Squamous differentiation. j Micropapillary differentiation. k Mitosis level 1. l Mitosis level 2. m Mitosis level 3.
n Apoptosis score 1. o Apoptosis score 3. p Capillary proliferation in fibrovascular core of papilla
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in the histological grading of PUC.
The importance of mitotic count has previously been
emphasized for histological grading of NMIPUCa [22, 23].
Pich et al. showed that a high proliferative index is the
most important recurrence-predictor among LMP and
low-grade tumors [24]. Akkalp et al. also emphasized that
higher mitotic activity (> 5/single high-power field) is a
strong predictor for recurrence in Ta PUCa [25]. The
studies indicate that proliferative activity can play an
adjunctive role in histologic grading (even in low grade tu-
mors) and prediction of recurrence or invasiveness, as also
shown in this study. However, the criteria for prolifer-
ative activity were variable, including a mitotic countper one or 10 high power fields in any level of the
neoplastic epithelium, and cut-off values for AgNOR
and Ki-67. Considering that urothelial neoplasms are
bulky, mitotic counting in high-power fields might be
inconsistent and discordant.
Mitotic level has not received much attention either.
The upper level of mitosis (level 3 mitosis) correlated
with increased mitotic count and worse clinical outcome
in our cohort. If a bulky mass is evaluated for the level
of mitosis, the mitotic-specific marker, phospohistamine
H3 (PHH3), can be useful for rapid detection of the
mitotic level. PHH3 has been used for grading of upper-
tract urothelial carcinoma [26]. Since the mitotic level
and count were measurable, reproducible, and the most
Table 3 Univariate analysis of factors associated with recurrence of PUC-Ta
Variable Category Odds ratio 95% Confidence Interval P-value
Age 1.00 0.97-1.03 0.9401
Sex man vs. woman 1.11 0.50-2.47 0.7908
No of tumor 0.34 0.17-0.67 0.0021*
Size of tumor 2.27 1.05-5.07 0.0399*
Papillary fusion 2 vs 1 1.50 0.65-3.50 0.3430
3 vs 1 1.60 0.74-3.50 0.2348
Umbrella cell 2 vs. 1 0.95 0.44-2.07 0.9020
3 vs. 1 1.19 0.52-2.75 0.6723
Discohesiveness 2 vs. 1 1.93 0.80-4.78 0.1480
3 vs. 1 1.57 0.71-3.53 0.2682
Cell density 2 vs. 1 1.62 0.69-3.88 0.2737
3 vs. 1 0.88 0.37-2.08 0.7719
Nuclear pleomorphism 2 vs. 1 0.47 0.21-1.03 0.0621
3 vs. 1 0.39 0.14-1.03 0.0599
4 vs. 1 3.84 0.58-76.11 0.2324
Multinucleated giant cell 1 vs. 0 1.14 0.58-2.24 0.7041
Loss of polarity 2 vs. 1 1.03 0.41-2.59 0.9557
3 vs. 1 0.82 0.29-2.26 0.6981
Hyperchromasia 2 vs. 1 1.36 0.67-2.79 0.3904
3 vs. 1 0.97 0.26-3.47 0.9604
Nuclear groove 2 vs. 1 1.83 0.86-3.96 0.1184
3 vs. 1 1.60 0.65-3.99 0.3079
Prominent nucleoli 2 vs. 1 1.12 0.56-2.23 0.7491
3 vs. 1 0.81 0.15-3.90 0.7903
Whorling pattern 1 vs. 0 1.07 0.55-2.11 0.8327
Necrosis 2 vs 1 0.98 0.39-2.48 0.9694
3 vs 1 0.77 0.21-2.58 0.6680
4 vs 1 1.47 0.54-4.14 0.4490
Divergent histology 2.04 0.73-8.10 0.2172
Mitotic count 1.03 1.00-1.07 0.0468*
Mitotic count (CAT) 2 vs. 1 4.62 1.89-11.98 0.0011
3 vs. 1 2.52 0.94-6.95 0.0684
4 vs. 1 3.15 1.22-8.46 0.0193*
Mitotic level 2 vs. 1 2.13 0.83-5.70 0.1229
3 vs. 1 4.44 1.88-11.18 0.0010*
Apoptosis 2 vs 1 1.15 0.53-2.50 0.7246
3 vs 1 1.09 0.24-4.82 0.9116
Capillary proliferation 1.05 1.01-1.10 0.0136*
No Number, CAT Categorical variable; *P < 0.05
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analysis, we strongly recommended that these factors
should be included as essential parameters in histo-
logical grading of PUC, even though identifying mitoses
in an entire specimen requires marked effort.HG tumors in the WHO 2004 and 2016 classification
cover wide ranges of tumors from immediately above low-
grade to highly anaplastic tumors. Recently, Cheng and
his colleges suggested a four-tiered grading system that in-
cluded grade 4, which consisted of an anaplastic group,
Table 4 Univariate analysis of factors associated with progression of PUC- Ta
Variable Category Odds ratio 95% Confidence Interval P-value
Age 1.05 1.01-1.09 0.0095*
Sex man vs. woman 1.06 0.46-2.7 0.8893
No of tumor 0.61 0.29-1.27 0.1856
Size of tumor 1.40 0.62-3.03 0.4012
Papillary fusion 2 vs 1 1.27 0.52-3.04 0.5871
3 vs 1 0.89 0.36-2.13 0.8044
Umbrella cell 2 vs. 1 1.82 0.64-5.13 0.2590
3 vs. 1 2.71 0.96-7.62 0.0591
Discohesiveness 2 vs. 1 1.30 0.49-3.26 0.5841
3 vs. 1 1.38 0.58-3.2 0.4579
Cell density 2 vs. 1 2.02 0.56-9.58 0.3165
3 vs. 1 5.40 1.73-23.89 0.0093*
Nuclear pleomorphism 2 vs. 1 0.72 0.26-2.06 0.5331
3 vs. 1 3.18 1.25-8.68 0.0180*
4 vs. 1 1.46 0.19-7.53 0.6683
Multinucleated giant cell 1 vs. 0 1.56 0.75-3.24 0.2337
Loss of polarity 2 vs. 1 1.17 0.35-3.86 0.798
3 vs. 1 2.70 0.82-8.93 0.104;
Hyperchromasia 2 vs. 1 2.42 1.16-5.2 0.0200*
3 vs. 1 1.75 0.71-4.32 0.2206
Nuclear groove 2 vs. 1 9.26 3.44-26.31 0.0000*
3 vs. 1 5.28 1.68-23.39 0.0105*
Prominent nucleoli 2 vs. 1 0.00 NA 0.9889
3 vs. 1 0.37 0.14-0.87 0.0314*
Whorling pattern 1 vs. 0 1.25 0.26-4.87 0.7550
Necrosis 2 vs 1 2.04 0.70-5.59 0.1747
3 vs 1 5.58 2.00-15.73 0.0010*
4 vs 1 2.47 0.83-6.90 0.0903
Divergent histology 1.70 0.68-3.98 0.2222
Mitotic count 1.06 1.03-1.09 0.0000*
Mitotic count(CAT) 2 vs. 1 8.72 2.1-59.47 0.0076*
3 vs. 1 8.45 1.8-60.71 0.0124*
4 vs. 1 24.80 6.59-162.78 0.0000*
Mitotic level 2 vs. 1 7.20 1.23-136.92 0.0689
3 vs. 1 15.51 3.1-282.16 0.0083*
Apoptosis 2 vs 1 2.18 0.97-4.84 0.0559
3 vs 1 3.40 0.94-11.44 0.0501*
Capillary proliferation 1.03 1-1.07 0.0673
NA Not available, CAT Categorical variable; *P < 0.05
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Because we agreed with the assignment of such an upper
grade, the second step of our newly proposed grading
scheme was focused on the selection of a more aggressive
group. Four additional histological parameters (mitotic
count, nuclear pleomorphism capillary proliferation, anddivergent histology) were used. We assigned tumors as
grade 4 when high-level mitosis, with more than 10 mi-
toses per 10 high-power fields, and any of the following
were present: divergent histology, nuclear pleomorphism
of more than 20-fold, and more than 20 capillary lumens
per papillary core. The other two upgrading schemes
Table 5 Comparison of AUC for predicting PUC-Ta tumor recurrence between previous grading systems and our proposed grading
system
Old_grades AUC-Old_grades (se) Proposed_grade AUC-Proposed_grade Old vs. new grade p-value
#1 0.686 (0.044) 1 0.709 (0.043) 0.3188
2 0.715 (0.043) 0.2784
3 0.703 (0.044) 0.4289
#2 0.688 (0.045) 1 0.709 (0.043) 0.3800
2 0.715 (0.043) 0.3215
3 0.703 (0.044) 0.5003
#3 0.685 (0.045) 1 0.709 (0.043) 0.2809
2 0.715 (0.043) 0.2516
3 0.703 (0.044) 0.3599
#1:2004 WHO grading system (low grade/high grade); #2: 1973 WHO grading system (TCC grade 1,2, and 3); #3:Cheng et al. ‘s grading
system [G1/G2/G3/G4-Anaplastic]
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but slightly different from this scheme.
Capillary proliferation has been evaluated in terms of
the number of capillary lumina per papillary core that
was cross-sectioned, and microvessel density (MVD) has
been studied as a prognostic factor in many solid tumors
[28, 29]. MVD could not be determined in this study, be-
cause endothelial marker immunostaining was performed
in a limited number of cases of Ta tumors. However, we
evaluated the light microscopic neovascularization by
counting the number of capillary lumina in the most vaso-
proliferative papillary core. The presence of more than 20
capillary lumina was correlated with a worse clinical
outcome.
A divergent histology was defined as identifiable histo-
logical features differing from the usual urothelial
carcinoma. A significant number of high-grade urothelial
carcinomas demonstrated glandular or squamous differ-
entiation. In this study, tumors with divergent histology
showed a worse clinical outcome than those that were
pure urothelial carcinomas. The divergent histology could
represent a dedifferentiation with molecular events result-
ing in a gain of function. Cheng et al. classified tumors
with divergent differentiation, such as the nested variant,
micropapillary variant, plasmacytoid variant, sarcomatoid
carcinoma, small-cell carcinoma, large-cell undifferenti-
ated carcinoma, and pleomorphic giant cell carcinoma, as
grade 4 tumors [3]. In our univariate analyses, divergent
histology was associated with progression of PUC-T1, but
it showed less statistical significance in PUC-Ta, with a P-
value of 0.2. Most histological parameters played no
significant roles in the clinical outcome of PUC-T1, except
for divergent histology. This indicated that the presence of
divergent differentiation should be considered, particularly
in invasive carcinoma. The reason for the reduced signifi-
cance of divergent histology in the prediction of clinical
outcome in PUC-Ta may be related to the low frequency
of Ta stage tumors. Aggressive tumors with a divergenthistology were more apparent in the invasive stage (T1)
and were not usually detected at the Ta stage. Thus, we
included divergent histology as one of adverse histological
parameters for upgrading. Large cohort studies of PUC-Ta
with a significant number of tumors with divergent histo-
logic differentiation may be needed to verify whether this
parameter has a clear biological impact.
Necrosis or apoptosis may be detected easily in a low-
power view, but differentiation between these two features
was not easy. In addition, degeneration of the papillary
cores with dystrophic calcification could be confused with
necrosis.
The newly proposed grading system designed here was
compared with previous grading systems. Even though
the difference in the AUCs between them was not statis-
tically significant, the AUCs of the new grading system
were larger than those of the previous grading systems
for the prediction of PUC-Ta recurrence. The former
AUC was more than 0.7 (p < 0.05), but that of the latter
was less than 0.7. In addition, our proposed grading
system was focused on only few, but the most powerful
histological parameters, which are not descriptive or sub-
jective, are rather quantifiable and are more reproducible,
for practical use. Therefore, our system may be a better
option to use as a grading system if it has a similar power
for the prediction of the clinical outcome of PUC-Ta.
Because this study was not prospectively designed, with
a controlled biopsy protocol and treatment, the treatment
factors cannot be considered in the clinical outcome.
Resection only vs. intravesical chemo/Bacille de Calmette-
Guérin (BCG) treatment cannot be separately reviewed
among the same grade and stage tumors. However, this
study is valuable because it provided a comprehensive
analysis of all histological parameters, including mitotic
level and count, through a nationwide multicenter study,
involving experienced uropathologists.
Although diagnostic improvement should be verified
by means of a kappa value, we were unable to do so in
Kwon et al. Diagnostic Pathology  (2017) 12:54 Page 11 of 12this study. In the near future, we will collect “gray zone”
tumors, with divergent designations by pathologists, and
apply the new grading system to determine whether it
allows improved diagnosis.
Conclusion
The mitotic level based on the initial biopsy appears to
be an independent predictor of the PUCa-Ta outcome.
This finding could potentially help distinguish between
low and high grade tumors in borderline lesions. There-
fore, this result may help in selecting patients for a
therapeutic strategy, based on the initial biopsy of NMI-
PUC of the bladder.
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